Eliana Merle from Barclays issued a price target of $18.00 for SGMT on 2026-09-09 07:19:00.The adjusted price target was set to $18.00.At the time of the announcement, SGMT was trading at $10.71.The overall price target consensus is at $7.00 with high price of $8.00, low price of $6.00, and median price is at $7.00.SGMT currently...
Barclays analyst issues OVERWEIGHT recommendation for SGMT on September 9, 2026 07:19AM ET. SGMT was trading...
Key Points - Pomerantz Law Firm, Wolf Haldenstein, Robbins LLP, Berger Montague PC, Bronstein, Gewirtz &...
Key Points - Multiple law firms have filed class action lawsuits against Hyliion Holdings Corp. -...
Key Points - Multiple investor rights law firms are notifying Capricor Therapeutics, Inc. investors of upcoming...
Eliana Merle from Barclays issued a price target of $18.00 for SGMT on 2026-09-09 07:19:00.The adjusted price target was set to $18.00.At the time of the announcement, SGMT was trading...
from Loop Capital Markets issued a price target of $500.00 for DAVE on 2026-09-08 20:56:33.The adjusted price target was set to $500.00.At the time of the announcement, DAVE was trading...
Kambiz Yazdi from BTIG issued a price target of $15.00 for ABSI on 2026-09-08 11:06:02.The adjusted price target was set to $15.00.At the time of the announcement, ABSI was trading...
Richard Baldry from Roth Capital issued a price target of $7.00 for EGAN on 2026-09-08 00:07:28.The adjusted price target was set to $7.00.At the time of the announcement, EGAN was...
from D.A. Davidson issued a price target of $22.00 for MAMA on 2026-09-04 13:04:14.The adjusted price target was set to $22.00.At the time of the announcement, MAMA was trading at...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
